Iovance’s Amtagvi Receives Health Canada Approval for Advanced Melanoma
ReutersAug 18, 2025 8:18 PM
Aug 18 (Reuters) - Iovance Biotherapeutics Inc IOVA.O:
IOVANCE’S AMTAGVI® (LIFILEUCEL) RECEIVES HEALTH CANADA APPROVAL FOR ADVANCED MELANOMA
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Oracle Q1 FY2026 Earnings: Can Cloud and AI Drive the Next Stock Rally?
TradingKey - Oracle Corporation (NYSE: ORCL) will report Q1 FY2026 results after the close on Tuesday, September 9, 2025, with the webcasted conference call scheduled for 4:00 PM CT / 5:00 PM ET, making the print a fresh read-through on enterprise cloudTradingKey
4 hours ago
What Is World Liberty Financial? Can WLFI Sustain Its High Valuation?
TradingKey – On September 1st, WLFI was simultaneously listed on major global cryptocurrency exchanges — including Coinbase, Binance, and OKX — a rarity inWorld Liberty Financial is a decentralized finance (DeFi) platform led by the Trump family. It offers staking and lending, a USD-pegged stablecoiTradingKey
5 hours ago
U.S. August Nonfarm Payroll Preview: Risks Focus on Downward Revision of July Data
TradingKey - On 5 September 2025, the U.S. Department of Labour will release the August Non-Farm Payrolls report. The market widely expects August to see an addition of 75,000 non-farm jobs, roughly in line with July’s 73,000.TradingKey
Thu, Sep 4
Unlocking Gold’s Next Leg: $4,000 in Reach by 2025？
TradingKey - Gold has kicked off a fresh uptrend in early September, breaking out of months of compression and reclaiming key territory. The decisive move above $3,500 establishes a new support base and puts higher objectives back on the table for the weeks aheadTradingKey
Thu, Sep 4
US NFP Nightmares Preview: A Tiny August Revision, a Huge Annual Benchmark Cut And a Fed in Flux
TradingKey - Wall Street expects modest job growth and a rebound in the unemployment rate in August NFP report, a balanced outcome that could support a September rate cut. However, a massive downward revision — a “terrifying scene” — and anomalies on the supply side could plunge the Fed into deeperTradingKey
Wed, Sep 3
 (1).jpg)
Tradingkey
